腫瘍内科について

歴史・論文集

わが国で最初に開設された
本格的な腫瘍内科です

歴史

わが国で最初に開設された本格的な腫瘍内科として2002年に発足し、初代教授には第四内科教授であった福岡正博先生が就任され、2007年に中川和彦教授に引き継がれ現在に至ります。
現在は医局内に約40名の医師が所属し、その内の半数以上ががん薬物療法専門医の資格を有しています。

当医局はこれまでも、多くの優秀な人材を輩出してきました。

当医局に在籍されたことがある先生方

  • 和歌山県立医科大学第三内科・山本信之教授
  • 関西医科大学呼吸器腫瘍内科・倉田宝保教授
  • 大阪大学消化器癌先進化学療法開発学・佐藤太郎教授
  • 国立がん研究センター中央病院乳腺腫瘍内科・田村研治科長
  • 九州大学病院呼吸器内科・岡本勇准教授
  • 大阪医科大学附属病院臨床研究センター・藤阪保仁センター長
  • 昭和大学先端がん治療研究所・鶴谷純司教授

ほか多数

論文集

2019年

Title Authors Journal
[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. Takegawa N, Tsurutani J, Kawakami H, Yonesaka K, Kato R, Haratani K, Hayashi H, Takeda M, Nonagase Y, Maenishi O, Nakagawa K. Int J Cancer. 2019 in press
A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing. Sakai K, Takeda M, Shimizu S, Takahama T, Yoshida T, Watanabe S, Iwasa T, Yonesaka K, Suzuki S, Hayashi H, Kawakami H, Nonagase Y, Tanaka K, Tsurutani J, Saigoh K, Ito A, Mitsudomi T, Nakagawa K, Nishio K. Sci Rep.9(1)11340,2019
A Phase II Study of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer who Responded to Prior PD-1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L). Akamatsu H, Teraoka S, Koh Y, Yamanaka T, Yamamoto N, Nakagawa K. Clin Lung Cancer.20(2)139-141,2019
A Case of Metastatic Malignant Breast Adenomyoepithelioma with a Codon-61 Mutation of HRAS Watanabe S, Otani T, Iwasa T, Takahama T, Takeda T, Sakai K, Nishio K, Ito A, Nakagawa K. Clinical Breast Cancer. 2019 in press
An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC. Yonesaka K, Takegawa N, Watanabe S, Haratani K, Kawakami H, Sakai K, Chiba Y, Maeda N, Kagari T, Hirotani K, Nishio K, Nakagawa K. Oncogene.38(9)1398-1409,2019
Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study). Akamatsu H, Koh Y, Okamoto I, Fujimoto D, Bessho A, Azuma K, Morita S, Yamamoto N, Nakagawa K. Lung Cancer. 131128-133,2019
Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT). Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Hirano J, Namba Y, Ohe Y. Clin Cancer Res.2019 in press
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J. J Clin Oncol. 2019 in press
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Ohe Y, Imamura F, Nogami N, Okamoto I, Kurata T, Kato T, Sugawara S, Ramalingam SS, Uchida H, Hodge R, Vowler SL, Walding A, Nakagawa K. Jpn J Clin Oncol. 49(1)29-36,2019
DELIVER (JACCRO GC-08) trial: discover novel host-related immune-biomarkers for nivolumab in advanced gastric cancer. Sunakawa Y, Inoue E, Matoba R, Kawakami H, Sato Y, Nakajima TE, Muro K, Ichikawa W, Fujii M. Future Oncol. 2019 May 29. doi: 10.2217/fon-2019-0167. [Epub ahead of print]
Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells. Yonesaka K, Kobayashi Y, Hayashi H, Chiba Y, Mitsudomi T, Nakagawa K. Oncol Rep.41(2)1059-1066,2019
Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer. Corral J, Mok TS, Nakagawa K, Rosell R, Lee KH, Migliorino MR, Pluzanski A, Linke R, Devgan G, Tan W, Quinn S, Wang T, Wu YL. Future Oncol. 15(24)2795-2805,2019
First-and-Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naïve EGFR Mutation-Positive Non-Small Cell Lung Cancer? Masayuki Takeda and Kazuhiko Nakagawa International Journal of Molecular Sciences20(1)E146,2019
First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer. Kishi K, Sakai H, Seto T, Kozuki T, Nishio M, Imamura F, Nokihara H, Satouchi M, Nakagawa S, Tahata T, Nakagawa K. Cancer Treat Res Commun. 2019 in press
Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cnacer negative for EGFR mutation and ALK fusion. Hitomi Sakai, Msayuki Takeda, Kazuko Sakai, Yasushi Nakamura, Akihiko Ito, Hidetoshi Hayashi, Koru Tanaka, Kazuto Nishio, Kazuhiko Nakagawa Lung Cancer 12759-65,2019
Incidence of opioid-induced constipation in Japanese patients with cancer pain: A prospective observational cohort study. Tokoro A, Imai H, Fumita S, Harada T, Noriyuki T, Gamoh M, Akashi Y, Sato H, Kizawa Y. Cancer Med. 2019 Jun 24. doi: 10.1002/cam4.2341. [Epub ahead of print]
Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC. Sugawara S, Nakagawa K, Yamamoto N, Nokihara H, Ohe Y, Nishio M, Takahashi T, Goto K, Maemondo M, Ichinose Y, Seto T, Sakai H, Gemma A, Imamura F, Shingyoji M, Saka H, Inoue A, Takeda K, Okamoto I, Kiura K, Morita S, Tamura T. Int J Clin Oncol. 24(5)485-493,2019
KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer. Nishio M, Takahashi T, Yoshioka H, Nakagawa K, Fukuhara T, Yamada K, Ichiki M, Tanaka H, Seto T, Sakai H, Kasahara K, Satouchi M, Han SR, Noguchi K, Shimamoto T, Kato T. Cancer Sci.110(3)1012-1020,2019
Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis. Zhou Q, Wu YL, Corral J, Nakagawa K, Garon EB, Sbar EI, Wang T, Sandin R, Noonan K, Gernhardt D, Mok TS. Future Oncol. 15(13)1481-1491,2019
Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer. Watanabe S, Hayashi H, Haratani K, Shimizu S, Tanizaki J, Sakai K, Kawakami H, Yonesaka K, Tsurutani J, Togashi Y, Nishio K, Ito A, Nakagawa K. Cancer Sci.110(1)52-60,2019
New Era for Next-Generation Sequencing in Japan. Takeda M, Sakai K, Takahama T, Fukuoka K, Nakagawa K, Nishio K. Cancers (Basel). 11(6 E742.),2019
Percutaneous transthoracic needle biopsy of the lung in the era of precision medicine Hitomi Sakai and Masayuki Takeda J Thorac Dis. 2019 May; 11(Suppl 9): S1213-S1215.
Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance. Creelan BC, Gray JE, Tanvetyanon T, Chiappori AA, Yoshida T, Schell MJ, Antonia SJ, Haura EB. Br J Cancer. 2019 Apr;120(8):791-796.
Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L). Kimura T, Kawaguchi T, Chiba Y, Yoshioka H, Watanabe K, Kijima T, Kogure Y, Oguri T, Yoshimura N, Niwa T, Kasai T, Hayashi H, Ono A, Asai K, Tanaka H, Yano S, Yamamoto N, Nakanishi Y, Nakagawa K. Jpn J Clin Oncol. 2019 in press
Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L). Akamatsu H, Teraoka S, Morita S, Katakami N, Tachihara M, Daga H, Yamamoto N, Nakagawa K. Clin Lung Cancer.20(4)e492-e494,2019
Phase II Trial of 5-Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer. Ueda H, Kawakami H, Nonagase Y, Takegawa N, Okuno T, Takahama T, Takeda M, Chiba Y, Tamura T, Nakagawa K. Oncologist.24(2)163-e76,2019
Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site. Hayashi H, Kurata T, Takiguchi Y, Arai M, Takeda K, Akiyoshi K, Matsumoto K, Onoe T, Mukai H, Matsubara N, Minami H, Toyoda M, Onozawa Y, Ono A, Fujita Y, Sakai K, Koh Y, Takeuchi A, Ohashi Y, Nishio K, Nakagawa K. J Clin Oncol. 37(7)570-579,2019
Reply to A.-M. Conway et al. Hayashi H, Nishio K, Nakagawa K. J Clin Oncol. 2019 in press
Safety and Efficacy of Alectinib in a Patient With Advanced NSCLC Undergoing Hemodialysis. Suzuki S, Haratani K, Takahama T, Watanabe S, Takegawa N, Hayashi H, Takeda M, Yonesaka K, Nakagawa K. J Thorac Oncol. 14(3):e50-e52,2019
Safety and Efficacy of Alectinib in a Patient With Advanced NSCLC Undergoing Hemodialysis. Suzuki S, Haratani K, Takahama T, Watanabe S, Takegawa N, Hayashi H, Takeda M, Yonesaka K, Nakagawa K. J Thorac Oncol. 14(3):e50-e52,2019
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen LT, Kang YK. Ann Oncol. 2019 Feb 1;30(2):250-258.
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N. Lung Cancer. 132126-131,2019
Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer. Watanabe S, Yonesaka K, Tanizaki J, Nonagase Y, Takegawa N, Haratani K, Kawakami H, Hayashi H, Takeda M, Tsurutani J, Nakagawa K. Cancer Med.2019 in press
Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies. Horinouchi H, Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, Takahashi T, Saka H, Takenoyama M, Katakami N, Tanaka H, Takeda K, Satouchi M, Isobe H, Maemondo M, Goto K, Hirashima T, Minato K, Sumiyoshi N, Tamura T. Cancer Med. 2019 in press
Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer. Nonagase Y, Takeda M, Azuma K, Hayashi H, Haratani K, Tanaka K, Yonesaka K, Ishii H, Hoshino T, Nakagawa K. Thorac Cancer. 2019 in press

2018年

Title Authors Journal
A case of ALK-rearranged non-small cell lung cancer that responded to ceritinib after development of resistance to alectinib. Makuuchi Y, Hayashi H, Haratani K, Tanizaki J, Tanaka K, Takeda M, Sakai K, Shimizu S, Ito A, Nishio K, Nakagawa K. Oncotarget. 2018 May 1;9(33):23315-23319.
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K. JAMA Oncol.4(3)374-378, 2018
B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity. Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, Takahama T, Tanaka K, Hayashi H, Takeda M, Kato S, Maenishi O, Sakai K, Chiba Y, Okabe T, Kudo K, Hasegawa Y, Kaneda H, Yamato M, Hirotani K, Miyazawa M, Nishio K, Nakagawa K. Clin Cancer Res.24(11)2653, 2018
Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2. Takeda M, Sakai K, Hayashi H, Tanaka K, Tanizaki J, Takahama T, Haratani K, Nishio K, Nakagawa K. Oncotarget.9(30)21132-21140, 2018
Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor. Jang J, Son J, Park E, Kosaka T, Saxon JA, De Clercq DJH, Choi HG, Tanizaki J, Eck MJ, Jänne PA, Gray NS. Angew Chem Int Ed Engl. 2018 Sep 3;57(36):11629-11633.
Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G). Miura Y, Sukawa Y, Hironaka S, Mori M, Nishikawa K, Tokunaga S, Okuda H, Sakamoto T, Taku K, Nishikawa K, Moriwaki T, Negoro Y, Kimura Y, Uchino K, Shinozaki K, Shinozaki H, Musha N, Yoshiyama H, Tsuda T, Miyata Y, Sugimoto N, Shirakawa T, Ito M, Yonesaka K, Yoshimura K, Boku N, Nosho K, Takano T, Hyodo I. Gastric Cancer. 2018 Jan;21(1):84-95. doi: 10.1007/s10120-017-0725-6. Epub 2017 May 11.
HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. Sakai H, Tsurutani J, Iwasa T, Komoike Y, Sakai K, Nishio K, Nakagawa K. Breast Cancer. 25(5)605-613, 2018
Immune-Related Adverse Events-A Novel Prediction of Nivolumab Efficacy?-Reply. Haratani K, Hayashi H, Nakagawa K. JAMA Oncol.4(7)1017-1018, 2018
In Reply. Tanizaki J, Chiba Y, Haratani K, Hayashi H, Nakagawa K. J Thorac Oncol.13(5)e86-e87,2018
Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer. Nakatani Y, Kawakami H, Ichikawa M, Yamamoto S, Otsuka Y, Mashiko A, Takashima Y, Ito A, Nakagawa K, Arima S. Invest New Drugs. 2018 Apr 6. doi: 10.1007/s10637-018-0596-7.
Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC. Kato R, Hayashi H, Sano K, Handa K, Kumode T, Ueda H, Okuno T, Kawakami H, Matsumura I, Kudo M, Nakagawa K. J Thorac Oncol.13(12)e239-e241,2018
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Kato K, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Nakajima TE, Shitara K, Kawakami H, Tsushima T, Yoshino T, Lordick F, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY. Ann Oncol. 2018 Nov 22. doi: 10.1093/annonc/mdy502. [Epub ahead of print] PubMed PMID: 30475956.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Muro K, Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Kato K, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Nakajima TE, Shitara K, Kawakami H, Narita Y, Yoshino T, Van Cutsem E, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY. Ann Oncol. 2018 Nov 22. doi: 10.1093/annonc/mdy498. [Epub ahead of print] PubMed PMID: 30475943.
Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Tanizaki J, Haratani K, Hayashi H, Chiba Y, Nakamura Y, Yonesaka K, Kudo K, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Ito A, Nakagawa K. J Thorac Oncol. 13(1)97-105,2018
Randomized, Open-Label Phase II Study Comparing Capecitabine-Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naïve Patients with HER2-Negative Advanced Gastric Cancer: OGSG1105, HERBIS-4A Trial. Kawakami H, Takeno A, Endo S, Makari Y, Kawada J, Taniguchi H, Tamura S, Sugimoto N, Kimura Y, Tamura T, Fujitani K, Sakai D, Shimokawa T, Kurokawa Y, Satoh T. Oncologist. 2018 Aug 16. pii: theoncologist.2018-0175. doi: 10.1634/theoncologist.2018-0175. [Epub ahead of print]
Gankyrin Contributes to Tumorigenesis and Chemoresistance in Sporadic Colorectal Cancer. Sakurai T, Komeda Y, Nagai T, Kamata K, Minaga K, Yamao K, Takenaka M, Hagiwara S, Watanabe T, Nishida N, Kashida H, Nakagawa K, Kudo M. Digestion. 41-9,2018
Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF Mutated human Colorectal Cancer. Zhang P, Kawakami H, Liu W, Dr. Zeng X, Strebhardt K, Tao K, Dr. Huang S, Sinicrope F. Mol Cancer Res. 2018 Mar;16(3):378-389. doi: 10.1158/1541-7786.MCR-17-0404. Epub 2017 Dec 12.
Treatment of EGFR mutation-positive non-small cell lung cancer complicated by Trousseau syndrome with gefitinib followed by osimertinib: a case report. Nonagase Y, Takeda M, Tanaka K, Hayashi H, Iwasa T, Nakagawa K. Oncotarget. 9(50)29532-29535, 2018
Two-step Intensity-modulated Radiation Therapy for Oropharyngeal Cancer: Initial Clinical Experience and Validation of Clinical Staging. Tatebe H, Doi H, Ishikawa K, Kawakami H, Yokokawa M, Nakamatsu K, Kanamori S, Shibata T, Kitano M, Nishimura Y Anticancer Res. 2018 Feb;38(2):979-986.
An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors. Furuse J, Kurata T, Okano N, Fujisaka Y, Naruge D, Shimizu T, Kitamura H, Iwasa T, Nagashima F, Nakagawa K. Cancer Chemother Pharmacol. 82(3)511-519,2018
An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy. Yamamoto N, Kenmotsu H, Goto K, Takeda K, Kato T, Takeda M, Horinouchi H, Saito I, Sarashina A, Tanaka T, Morsli N, Nakagawa K. Cancer Chemother Pharmacol.82(4)685-694,2018
A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L. Sasaki T, Seto T, Yamanaka T, Kunitake N, Shimizu J, Kodaira T, Nishio M, Kozuka T, Takahashi T, Harada H, Yoshimura N, Tsutsumi S, Kitajima H, Kataoka M, Ichinose Y, Nakagawa K, Nishimura Y, Yamamoto N, Nakanishi Y Br J Cancer. 119(6)675-682,2018
Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L). Hata A, Katakami N, Shimokawa M, Mitsudomi T, Yamamoto N, Nakagawa K. Clin Lung Cancer.19(6)e865-e869,2018
Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: A subgroup analysis of elderly patients. Nogami N, Nishio M, Okamoto I, Enatsu S, Suzukawa K, Takai H, Nakagawa K, Tamura T. Respir Investig.S2212-5345(18)30256-9,2018
Induction Chemo-radiation (50Gy) Followed by Surgery for Stage IIIA-N2 Non-small Cell Lung Cancer. Tanaka F, Yokomise H, Soejima T, Uramoto H, Yamanaka T, Nakagawa K, Yamamoto N, Nishimura Y, Niwa H, Okada M, Nakagawa T, Yamashita M. Ann Thorac Surg.106:(4)1018-1024,2018
Crizotinib Versus Chemotherapy in Asian Patients with Advanced ALK-positive Non-small Cell Lung Cancer. Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, Shaw AT, Hashigaki S, Ohki E, Usari T, Paolini J, Polli A, Wilner KD, Mok T. Cancer Res Treat.50(3)691-700, 2018
Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset. Kiura K, Imamura F, Kagamu H, Matsumoto S, Hida T, Nakagawa K, Satouchi M, Okamoto I, Takenoyama M, Fujisaka Y, Kurata T, Ito M, Tokushige K, Hatano B, Nishio M. Jpn J Clin Oncol. 48(4)367-375, 2018
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Kiura K, Widau RC, He S, Dalal R, Lee P, Nakagawa K. Clin Lung Cancer.19(3)213-220.e4, 2018
Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. Okamoto I, Morita S, Tashiro N, Imamura F, Inoue A, Seto T, Yamamoto N, Ohe Y, Nakagawa K, Fukuoka M Lung Cancer. 11714-19, 2018
Sterilized talc pleurodesis for malignant pleural effusions: a Phase II study for investigational new drug application in Japan. Saka H, Oki M, Kitagawa C, Kogure Y, Kojima Y, Saito AM, Ishida A, Miyazawa T, Takeda K, Nakagawa K, Sasada S, Negoro S Jpn J Clin Oncol.48(4)376-381, 2018
A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T. Breast.4067-75, 2018
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tang Y, Wilner KD, Blackhall F, Mok TS. J Clin Oncol. 36(22)2251-2258, 2018
Prognostic value of Lung Cancer Subscale in older patients with advanced non-small cell lung cancer: An integrated analysis of JCOG0207 and JCOG0803/WJOG4307L (JCOG1414A). Mizutani T, Ando M, Mizusawa J, Nakamura K, Fukuda H, Tsukada H, Abe T, Takeda K, Yokoyama A, Nakamura S, Nakagawa K, Yamamoto N, Ohe Y. J Geriatr Oncol. S1879-4068(18)30154-1, 2018
Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study. Fujiwara Y, Takeda M, Yamamoto N, Nakagawa K, Nosaki K, Toyozawa R, Abe C, Shiga R, Nakamaru K, Seto T. Oncotarget.9(34)23729-23737, 2018
ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer. Azuma K, Nishio M, Hayashi H, Kiura K, Satouchi M, Sugawara S, Hida T, Iwamoto Y, Inoue A, Takeda K, Ikeda S, Nakagawa T, Takeda K, Asahina S, Komatsu K, Morita S, Fukuoka M, Nakagawa K. Cancer Sci.109(8)2532-2538, 2018
Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Nishio M, Nakagawa K, Mitsudomi T, Yamamoto N, Tanaka T, Kuriki H, Zeaiter A, Tamura T. Lung Cancer.12137-40, 2018
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL. J Clin Oncol.36(22)2244-2250, 2018
Chemoradiotherapy in Elderly Patients With Non-Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301). Atagi S, Mizusawa J, Ishikura S, Takahashi T, Okamoto H, Tanaka H, Goto K, Nakagawa K, Harada M, Takeda Y, Nogami N, Fujita Y, Kasai T, Kishi K, Sawa T, Takeda K, Tomii K, Satouchi M, Seto T, Ohe Y. Clin Lung Cancer. 19(5)e619-e627, 2018
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations. Murakami H, Nokihara H, Hayashi H, Seto T, Park K, Azuma K, Tsai CM, Yang JC, Nishio M, Kim SW, Kiura K, Inoue A, Takeda K, Kang JH, Nakagawa T, Takeda K, Akazawa R, Kaneko Y, Shimazaki M, Morita S, Fukuoka M, Nakagawa K. Cancer Sci.109(9)2852-2862, 2018
A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non-small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L). Akamatsu H, Harada H, Tokunaga S, Yoshimura N, Ikeda H, Oizumi S, Sugimoto N, Takano T, Murakami H, Nishimura Y, Yamamoto N, Nakagawa K. Clin Lung Cancer.S1525-7304(18)30230-4, 2018

2017年

Title Authors Journal
A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study. Hayashi H, Chiba Y, Sakai K, Fujita T, Yoshioka H, Sakai D, Kitagawa C, Naito T, Takeda K, Okamoto I, Mitsudomi T, Kawakami Y, Nishio K, Nakamura S, Yamamoto N, Nakagawa K. Clin Lung Cancer. 18(6)719-723, 2017
A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. H Yoshioka, N Katakami, H Okamoto, Y Iwamoto, T Seto, T Takahashi, N Sunaga, S Kudoh, K Chikamori, M Harada, H Tanaka, H Saito, H Saka, K Takeda, N Nogami, N Masuda, T Harada, H Kitagawa, H Horio, T Yamanaka, M Fukuoka, N Yamamoto, K Nakagawa. Ann Oncol.28 (2);285-291.2017
Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer. Yonesaka K, Hirotani K, von Pawel J, Dediu M, Chen S, Copigneaux C, Nakagawa K. Lung Cancer.105,1-6,2017
Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer. Ueda H, Takeda M, Ueda S, Kawakami H, Okuno T, Takegawa N, Hayashi H, Tsurutani J, Tamura T, Ishikawa K, Nishimura Y, Nakagawa K. Oncotarget. 8(46)80286-80294,2017
Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer. Ogiya R, Niikura N, Kumaki N, Yasojima H, Iwasa T, Kanbayashi C, Oshitanai R, Tsuneizumi M, Watanabe KI, Matsui A, Fujisawa T, Saji S, Masuda N, Tokuda Y, Iwata H. Oncotarget. 2017 Oct 27;8(61):103671-103681.
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, Tamura T, Nishio K, Nakagawa K, Tsurutani J. Int J Cancer. 141(8)1682-1689,2017
Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study. Yokota T, Ogawa T, Takahashi S, Okami K, Fujii T, Tanaka K, Iwae S, Ota I, Ueda T, Monden N, Matsuura K, Kojima H, Ueda S, Sasaki K, Fujimoto Y, Hasegawa Y, Beppu T, Nishimori H, Hirano S, Naka Y, Matsushima Y, Fujii M, Tahara M. BMC Cancer. 2017 May 5;17(1):314.
Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A. Chiba M, Togashi Y, Bannno E, Kobayashi Y, Nakamura Y, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K. BMC Cancer. 2017 Apr 19;17(1):281. doi: 10.1186/s12885-017-3263-z. No abstract available.
Estimated risks of recurrence and mortality in lung cancer:comprehensive analysis by a population-based study. Junko Tanizaki, Hidetoshi Hayashi, Kazuhiko Nakagawa Translational Cancer Research 6(Suppl 1)S39-S41,2017
Expectation of a Decrease in Pain Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of Response to Morphine. Matsuoka H, Yoshiuchi K, Koyama A, Makimura C, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K, Nakagawa K. Int J Behav Med.2017 in press
HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy. Takegawa N, Yonesaka K. Clin Colorectal Cancer. 2017 Dec;16(4):247-251. doi: 10.1016/j.clcc.2017.03.001. Epub 2017 Mar 9. Review.
Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Hisato Kawakami, Junko Tanizaki, Kaoru Tanaka, Koji Haratani, Hidetoshi Hayashi, Masayuki Takeda, Ken Kamata, Mamoru Takenaka, Masatomo Kimura, Takaaki Chikugo, Takao Sato, Masatoshi Kudo, Akihiko Ito, Kazuhiko Nakagawa. Investigational New Drugs 35(4)529-536,2017
Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Hisato Kawakami, Junko Tanizaki, Kaoru Tanaka, Koji Haratani, Hidetoshi Hayashi, Masayuki Takeda, Ken Kamata, Mamoru Takenaka, Masatomo Kimura, Takaaki Chikugo, Takao Sato, Masatoshi Kudo, Akihiko Ito, Kazuhiko Nakagawa. Investigational New Drugs 2017 in press
MEK inhibitors against MET-amplified non-small cell lung cancer. Chiba M, Togashi Y, Tomida S, Mizuuchi H, Nakamura Y, Banno E, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K. Int J Oncol. 2016 Dec;49(6):2236-2244. doi: 10.3892/ijo.2016.3736. Epub 2016 Oct 17.
Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer. Makoto Nishio, Toyoaki Hida, Shinji Atagi, Hiroshi Sakai, Kazuhiko Nakagawa, Toshiaki Takahashi, Naoyuki Nogami, Hideo Saka, Mitsuhiro Takenoyama, Makoto Maomondo, Yuishiro Ohe, Hiroshi Nokihara, Tomonori Hirashima, Hiroshi Tanaka,Shiro Fujita, Koji Takeda, Koichi Goto, Miyako Satouchi, Hiroshi Isobe, Koishi Minato, Naoki Sumiyoshi, Tomohide Tamura. British Medical Journal2017 in press
Next-generation sequencing-based clinical testing for lung cancer in Japan Masayuki Takeda, Kazuko Sakai, Kazuhiko Nakagawa, Kazuto Nishio Transl Cancer Res 6(3)633-638,2017
Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab. Kato R, Hayashi H, Tanizaki J, Tanaka K, Takeda M, Nakagawa K. ESMO Open.2(1)e000145,2017
Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer. Shimizu T, Yonesaka K, Hayashi H, Iwasa T, Haratani K, Yamada H, Ohwada S, Kamiyama E, Nakagawa K. Cancer Chemother Pharmacol.79(3)489-495,2017
Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). Yamazaki N, Takenouchi T, Fujimoto M, Ihn H, Uchi H, Inozume T, Kiyohara Y, Uhara H, Nakagawa K, Furukawa H, Wada H, Noguchi K, Shimamoto T, Yokota K. Cancer Chemother Pharmacol. 2017 in press
Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy. Tambo Y, Hosomi Y, Sakai H, Nogami N, Atagi S, Sasaki Y, Kato T, Takahashi T, Seto T, Maemondo M, Nokihara H, Koyama R, Nakagawa K, Kawaguchi T, Okamura Y, Nakamura O, Nishio M, Tamura T. Invest New Drugs.2017 in press
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P, Pieters A, Kong Sanchez T, Fairchild J, Spigel D. J Clin Oncol.2017 in press
Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. Kubota K, Yoshioka H, Oshita F, Hida T, Yoh K, Hayashi H, Kato T, Kaneda H, Yamada K, Tanaka H, Ichinose Y, Park K, Cho EK, Lee KH, Lin CB, Yang JC, Hara K, Asato T, Nakagawa K. J Clin Oncol. 2017 Nov 10;35(32):3662-3670.
Prognostic Impact of Minimal Pericardial Effusion in Patients With Advanced Non-small-cell Lung Cancer. Kato R, Hayashi H, Chiba Y, Tanaka K, Takeda M, Nakagawa K. Clin Lung Cancer. 18(6)e449-e455,2017
Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer:a multicentre, randomised, open-label, phase 3trial. Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, Nishio M, KanedaH, Takayama K, Ishimoto O, Takeda K, Yoshioka H, Tachihara M, Sakai H, Goto K, Yamamoto N Lancet Oncol.2017 in press
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Kosaka T, Tanizaki J, Paranal RM, Endoh H, Lydon C, Capelletti M, Repellin CE, Choi J, Ogino A, Calles A, Ercan D, Redig AJ, Bahcall M, Oxnard GR, Eck MJ, Jänne PA. Cancer Res. 2017 May 15;77(10):2712-2721.
Retrospective study of unplanned hospital admission for metastatic cancer patients visiting the emergency department. Tanaka T, Taguri M, Fumita S, Okamoto K, Matsuo Y, Hayashi H. Support Care Cancer. 2017 in press
S-1 as an option for second-line treatment of NSCLC. Is the 'East Side Story' applicable in the West? Hayashi H, Mitsudomi T. Ann Oncol. 2017 Nov 1;28(11):2627-2629. doi: 10.1093/annonc/mdx519.
Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study). Matsuoka H, Tsurutani J, Chiba Y, Fujita Y, Terashima M, Yoshida T, Sakai K, Otake Y, Koyama A, Nishio K, Nakagawa K. BMC Cancer. 2017 Oct 6;17(1):674.
Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies. Mizukami T, Togashi Y, Naruki S, Banno E, Terashima M, de Velasco MA, Sakai K, Yoneshige A, Hayashi H, Fujita Y, Tomida S, Nakajima TE, Fujino T, Boku N, Ito A, Nakagawa K, Nishio K. Mol Carcinog.56(1);106-117.2017
T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung Cancer. Watanabe S, Yoshida T, Kawakami H, Takegawa N, Tanizaki J, Hayashi H, Takeda M, Yonesaka K, Tsurutani J, Nakagawa K. Mol Cancer Ther.-2563-2571,2017
The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancer. Gemmill RM, Nasarre P, Nair-Menon J, Cappuzzo F, Landi L, D'Incecco A, Uramoto H, Yoshida T, Haura EB, Armeson K, Drabkin HA. Sci Signal. 2017 Jan 17;10(462).
The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crino L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E J Thorac Oncol. 2017 in press
Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP. Tamura T, Kiura K, Seto T, Nakagawa K, Maemondo M, Inoue A, Hida T, Yoshioka H, Harada M, Ohe Y, Nogami N, Murakami H, Kuriki H, Shimada T, Tanaka T, Takeuchi K, Nishio M. J Clin Oncol. 2017 in press
Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer. Takeda M, Nakagawa K. Mol Clin Oncol. 6(1)3-6,2017.
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K. Ann Oncol. 28(7):1532-1539,2017
Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy. Tambo Y, Hosomi Y, Sakai H, Nogami N, Atagi S, Sasaki Y, Kato T, Takahashi T, Seto T, Maemondo M, Nokihara H, Koyama R, Nakagawa K, Kawaguchi T, Okamura Y, Nakamura O, Nishio M, Tamura T. Invest New Drugs.35(2)217-226,2017
Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). Yamazaki N, Takenouchi T, Fujimoto M, Ihn H, Uchi H, Inozume T, Kiyohara Y, Uhara H, Nakagawa K, Furukawa H, Wada H, Noguchi K, Shimamoto T, Yokota K. Cancer Chemother Pharmacol. 79(4)651-660,2017
Expectation of a Decrease in Pain Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of Response to Morphine. Matsuoka H, Yoshiuchi K, Koyama A, Makimura C, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K, Nakagawa K. Int J Behav Med.24(4)535-541,2017
Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP. Tamura T, Kiura K, Seto T, Nakagawa K, Maemondo M, Inoue A, Hida T, Yoshioka H, Harada M, Ohe Y, Nogami N, Murakami H, Kuriki H, Shimada T, Tanaka T, Takeuchi K, Nishio M. J Clin Oncol.35(14)1515-1521,2017
Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer. Hida T, Nishio M, Nogami N, Ohe Y, Nokihara H, Sakai H, Satouchi M, Nakagawa K, Takenoyama M, Isobe H, Fujita S, Tanaka H, Minato K, Takahashi T, Maemondo M, Takeda K, Saka H, Goto K, Atagi S, Hirashima T, Sumiyoshi N, Tamura T. Cancer Sci.108(5)1000-1006,2017
Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs. Matsuoka H, Kaneda H, Sakai K, Koyama A, Nishio K, Nakagawa K. Clin Lung Cancer.18(1)e85-e87,2017
Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset. Hida T, Satouchi M, Nakagawa K, Seto T, Matsumoto S, Kiura K, Nokihara H, Murakami H, Tokushige K, Hatano B, Nishio M. Jpn J Clin Oncol.1-7,2017
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T, Yang JC. J Natl Cancer Inst.109(6)2017
Incidence of carnitine deficiency in patients with cancer pain: A pilot study. Sakai K, Matsuoka H, Ohtake Y, Makimura C, Izumi H, Fujita Y, Otsuka M, Tsurutani J, Nishio K, Nakagawa K, Koyama A. Mol Clin Oncol. 6(3)331-333,2017
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T. Lancet.390(10089)29-39,2017
Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer. Makoto Nishio, Toyoaki Hida, Shinji Atagi, Hiroshi Sakai, Kazuhiko Nakagawa, Toshiaki Takahashi, Naoyuki Nogami, Hideo Saka, Mitsuhiro Takenoyama, Makoto Maomondo, Yuishiro Ohe, Hiroshi Nokihara, Tomonori Hirashima, Hiroshi Tanaka,Shiro Fujita, Koji Takeda, Koichi Goto, Miyako Satouchi, Hiroshi Isobe, Koishi Minato, Naoki Sumiyoshi, Tomohide Tamura. British Medical Journal1(4)e000108,2017
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P, Pieters A, Kong Sanchez T, Fairchild J, Spigel D. J Clin Oncol.34(31)3740-3748,2017
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Kiura K, Widau RC, He S, Dalal R, Lee P, Nakagawa K. Clin Lung Cancer. S1525-7304(17)30315-7,2017
Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study). Matsuoka H, Tsurutani J, Chiba Y, Fujita Y, Terashima M, Yoshida T, Sakai K, Otake Y, Koyama A, Nishio K, Nakagawa K. BMC Cancer.17(1)674,2017
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC. J Clin Oncol.35(36)4027-4034,2017
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Lancet Oncol. 18(11)1454-1466,2017
Prospective replication study implicates the catechol-O-methyltransferase Val158Met polymorphism as a biomarker for the response to morphine in patients with cancer. Matsuoka H, Makimura C, Koyama A, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K, Nakagawa K. Biomed Rep.7(4)380-384.2017
Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. Kubota K, Yoshioka H, Oshita F, Hida T, Yoh K, Hayashi H, Kato T, Kaneda H, Yamada K, Tanaka H, Ichinose Y, Park K, Cho EK, Lee KH, Lin CB, Yang JC, Hara K, Asato T, Nakagawa K. J Clin Oncol. 35(32)3662-3670,2017
Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid. Yanae M, Fujimoto S, Tane K, Tanioka M, Fujiwara K, Tsubaki M, Yamazoe Y, Morishima Y, Chiba Y, Takao S, Komoike Y, Tsurutani J, Nakagawa K, Nishida S. J Bone Oncol.818-22,2017
Lentinula edodes mycelia extract plus adjuvant chemotherapy for breast cancer patients: Results of a randomized study on host quality of life and immune function improvement. Nagashima Y, Yoshino S, Yamamoto S, Maeda N, Azumi T, Komoike Y, Okuno K, Iwasa T, Tsurutani J, Nakagawa K, Masaaki O, Hiroaki N. Mol Clin Oncol.7(3)359-366,2017
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer. Garon EB, Reck M, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Lee P, Dalal R, Liu J, He S, Treat J, Nakagawa K. Clin Lung Cancer.18(1)96-99,2017
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Soo RA, Yang JC, Sugawara S, Nishio M, Takahashi T, Goto K, Chang J, Maemondo M, Ichinose Y, Cheng Y, Lim WT, Morita S, Tamura T. Ann Oncol.28(11)2698-2706,2017
A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. Yoshioka H, Katakami N, Okamoto H, Iwamoto Y, Seto T, Takahashi T, Sunaga N, Kudoh S, Chikamori K, Harada M, Tanaka H, Saito H, Saka H, Takeda K, Nogami N, Masuda N, Harada T, Kitagawa H, Horio H, Yamanaka T, Fukuoka M, Yamamoto N, Nakagawa K. Ann Oncol.28(2)285-291,2017
The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crino L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E. J Thorac Oncol. 12(2)194-20,2017
A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. Yoshioka, N Katakami, H Okamoto, Y Iwamoto, T Seto, T Takahashi, N Sunaga, S Kudoh, K Chikamori, M Harada, H Tanaka, H Saito, H Saka, K Takeda, N Nogami, N Masuda, T Harada, H Kitagawa, H Horio, T Yamanaka, M Fukuoka, N Yamamoto, K Nakagawa. Ann Oncol.28 (2)285-291,2017
Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies. Mizukami T, Togashi Y, Naruki S, Banno E, Terashima M, de Velasco MA, Sakai K, Yoneshige A, Hayashi H, Fujita Y, Tomida S, Nakajima TE, Fujino T, Boku N, Ito A, Nakagawa K, Nishio K. Mol Carcinog.56(1)106-117,2017.

2016年

Title Authors Journal
A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. Shimizu T, Fukuoka K, Takeda M, Iwasa T, Yoshida T, Horobin J, Keegan M, Vaickus L, Chavan A, Padval M, Nakagawa K. Cancer Chemother Pharmacol. 77(5);997-1003 .2016
A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer. Tamiya M, Tamiya A, Kaneda H, Nakagawa K, Yoh K, Goto K, Okamoto H, Shimokawa T, Abe T, Tanaka H, Daga H, Takeda K, Hirashima T, Atagi S. Med Oncol.33(1);2.2016
A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study). Iwata T, Yoshino I, Yoshida S, Ikeda N, Tsuboi M, Asato Y, Katakami N, Sakamoto K, Yamashita Y, Okami J, Mitsudomi T, Yamashita M, Yokouchi H, Okubo K, Okada M, Takenoyama M, Chida M, Tomii K, Matsuura M, Azuma A, Iwasawa T, Kuwano K, Sakai S, Hiroshima K, Fukuoka J, Yoshimura K, Tada H, Nakagawa K, Nakanishi Y; West Japan Oncology Group. Respir Res.17(1);90.2016
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N, Nishio M, Ohe Y, Koue T, Nakamura T, Enatsu S, Lee P, Ferry D, Tamura T, Nakagawa K. Lung Cancer. 99;186-93 .2016
Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report. Nonagase Y, Okamoto K, Iwasa T, Yoshida T, Tanaka K, Takeda M, Kaneda H, Shimizu T, Tsurutani J, Nakagawa K. Anticancer Drugs. 2016 Mar;27(3):251-3.
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial. Takeda M, Yamanaka T, Seto T, Hayashi H, Azuma K, Okada M, Sugawara S, Daga H, Hirashima T, Yonesaka K, Urata Y, Murakami H, Saito H, Kubo A, Sawa T, Miyahara E, Nogami N, Nakagawa K, Nakanishi Y, Okamoto I. Cancer. 122(7);1050-9.2016
Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation. Tanizaki J, Banno E, Togashi Y, Hayashi H, Sakai K, Takeda M, Kaneda H, Nishio K, Nakagawa K. Lung Cancer. 101;43054.2016
Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. Inoue A, Yoshida K, Morita S, Imamura F, Seto T, Okamoto I, Nakagawa K, Yamamoto N, Muto S, Fukuoka M. Jpn J Clin Oncol.46(5);462-7 .2016
Clinical outcome of node-negative oligometastatic non-small cell lung cancer. Sakai K, Takeda M, Hayashi H, Tanaka K, Okuda T, Kato A, Nishimura Y, Mitsudomi T, Koyama A, Nakagawa K. Thorac Cancer.7(6);670-675.2016
Clinical outcome of node-negative oligometastatic non-small cell lung cancer. Sakai K, Takeda M, Hayashi H, Tanaka K, Okuda T, Kato A, Nishimura Y, Mitsudomi T, Koyama A, Nakagawa K. Thorac Cancer.7(6);670-675 .2016
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Goto K, Ohe Y, Shibata T, Seto T, Takahashi T, Nakagawa K, Tanaka H, Takeda K, Nishio M, Mori K, Satouchi M, Hida T, Yoshimura N, Kozuki T, Imamura F, Kiura K, Okamoto H, Sawa T, Tamura T; JCOG0605 investigators. Lancet Oncol.17(8);1147-57 .2016
Crizotinib for ALK rearrangement-positive non-small cell lung cancer patients with central nervous system metastasis Masayuki Takeda, Kazuhiko Nakagawa. Translational Cancer Research 5(3);1-3.2016
Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive for ALK translocation. Hayashi H, Nakagawa K. J Thorac Dis.8(10);E1311-E1316.2016
Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M, Oguri T, Tanaka H, Ebi N, Sawa T, Bessho A, Tachihara M, Akamatsu H, Bandoh S, Himeji D, Ohira T, Shimokawa M, Nakanishi Y, Nakagawa K, Nishio K. Oncotarget. 7(36);58492-58499.2016
FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. Hibi M, Kaneda H, Tanizaki J, Sakai K, Togashi Y, Terashima M, De Velasco MA, Fujita Y, Banno E, Nakamura Y, Takeda M, Ito A, Mitsudomi T, Nakagawa K, Okamoto I, Nishio K. Cancer Sci. 107(11);1667-1676.2016
Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2. Terashima M, Togashi Y, Sato K, Mizuuchi H, Sakai K, Suda K, Nakamura Y, Banno E, Hayashi H, De Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K. Clin Cancer Res. 2016 Jul 15;22(14):3663-71.
HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K Oncotarget. 2016;7(3):3453-60
HER3 and its ligand, heregulin, as targets for cancer therapy. Hisato Kawakami, Kimio Yonesaka Recent Patents on Anti-Cancer Drug Discovery 11(999);2016
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. Nonagase Y, Yonesaka K, Kawakami H, Watanabe S, Haratani K, Takahama T, Takegawa N, Ueda H, Tanizaki J, Hayashi H, Yoshida T, Takeda M, Chiba Y, Tamura T, Nakagawa K, Tsurutani J. Oncotarget.7(51);84860-84871.2016
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS. J Clin Oncol. 34(24);2858-65 .2016
Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer? Watanabe S, Hayashi H, Nakagawa K. Ann Transl Med.4(11);225.2016
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. Hisato Kawakami, Isamu Okamoto Gastric Cancer. 19(3);687-95.2016
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. Frank A. Sinicrope, Koichi Okamoto, Pashtoon M. Kasi, Hisato Kawakami Clin Gastroenterol Hepatol.14(5);651-8.2016
Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer. Hisato Kawakami, Shengbing Huang, Frank A. Krishnendu Pal, Debabrata Mukhopadhyay, Frank Sinicrope Mol Cancer Ther.15(12);3015-3027.2016
Pharmacokinetics of amrubicin in lung cancer patients with impaired hepatic function. Shinishiro Ryuge, Noriyuki Masuda, Nobuyuji Yamamoto, Toshiaki Takashi, Haruyasu Murakami, Koji Takeda, Haruko Daga, Kimio Yonesaka, Hiroshi Tsukuda, Kazuhiko Nakagawa, Kaoru Yanaka, Katsuyuki Kiura, Nagio Takigawa, Yoyoaki Hida, Takashi Seto, Masanori Yokoba, Shinzoh Kudoh, Takeshi Takagaki, Kazushige Shono, Hideo Kitagawa, Takeshi Kurihara, Masahiro Fukuoka. Cancer treatment and research communications9;81-87.2016
Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ NSCLC with or without prior crizotinib therapy. Hida T, Nakagawa K, Seto T, Satouchi M, Nishio M, Hotta K, Takahashi T, Ohe Y, Takeda K, Tatsuno M, Asakawa T, Shimada T, Tanaka T, Tamura T. Cancer Sci. 107(11);1642-1646.2016
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Shimizu T, Seto T, Hirai F, Takenoyama M, Nosaki K, Tsurutani J, Kaneda H, Iwasa T, Kawakami H, Noguchi K, Shimamoto T, Nakagawa K. Invest New Drugs.34(3);347-54 .2016
Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib. Azuma K, Hirashima T, Yamamoto N, Okamoto I, Takahashi T, Nishio M, Hirata T, Kubota K, Kasahara K, Hida T, Yoshioka H, Nakanishi K, Akinaga S, Nishio K, Mitsudomi T, Nakagawa K. ESMO Open. 1(4);e000063.2016
Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib. Watanabe S, Hayashi H, Okamoto K, Fujiwara K, Hasegawa Y, Kaneda H, Tanaka K, Takeda M, Nakagawa K. Clin Lung Cancer. 17(6);528-534.2016
Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC. J Clin Oncol.34(27);3258-66.2016
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, Satouchi M, Iwamoto Y, Kanehara M, Fujimoto D, Ikeda N, Murakami H, Daga H, Oguri T, Goto I, Imamura F, Sugawara S, Saka H, Nogami N, Negoro S, Nakagawa K, Nakanishi Y. J Clin Oncol. 34(27);3248-57 .2016
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. Shitara K, Yonesaka K, Denda T, Yamazaki K, Moriwaki T, Tsuda M, Takano T, Okuda H, Nishina T, Sakai K, Nishio K, Tokunaga S, Yamanaka T, Boku N, Hyodo I, Muro K. Cancer Sci. 2016 Dec;107(12):1843-1850. doi: 10.1111/cas.13098
Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. Nosaki K, Satouchi M, Kurata T, Yoshida T, Okamoto I, Katakami N, Imamura F, Tanaka K, Yamane Y, Yamamoto N, Kato T, Kiura K, Saka H, Yoshioka H, Watanabe K, Mizuno K, Seto T Lung Cancer. 2016 Nov;101:1-8.
Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression. Tanizaki J, Hayashi H, Kimura M, Tanaka K, Takeda M, Shimizu S, Ito A, Nakagawa K. Lung Cancer. 102;44-48.2016
Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor? Banno E, Togashi Y, Nakamura Y, Chiba M, Kobayashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K. Cancer Sci. 2016 Aug;107(8):1134-40. 
Spontaneous pneumothorax due to bronchopleural fistula following reirradiation for locoregionally recurrent squamous cell lung cancer. Ota T, Suzumura T, Sugiura T, Hasegawa Y, Yonesaka K, Makihara M, Tsukuda H, Tada T, Fukuoka M. Clin Case Rep. 2016 Apr 1;4(5):481-5. doi: 10.1002/ccr3.547. eCollection 2016 May
Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease. Watanabe S, Takeda M, Takahama T, Iwasa T, Tsurutani J, Tanizaki J, Shimizu T, Sakai K, Wada Y, Isogai N, Nishio K, Nakagawa K. Invest New Drugs.34(3);394-6 .2016
Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity. Ueda H, Hayashi H, Kudo K, Takeda M, Nakagawa K. Invest New Drugs.34(6);797-799.2016
Succsessful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR. Hitomi Sakai, Hidetoshi Hayashi, Tsutomu Iwasa, Yoshikazu Hasegawa, Masayuki Takeda, Kazuhiko Nakagawa ESMO Open. ;1-4.2016
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y; SELECT BC study group. Lancet Oncol. 17(1);33086.2016
The Efficacy and Safety of Sterile Graded Talc in Pleurodesis for Malignant Pleural Effusion: Phase II study Hideo Saka, Masahide Oki, Chiyoe Kitagawa, Yoshihito Kogure, Yuki Kojima, Akiko M. Siato, Atsuko Ishida, Terunao Miyazawa, Koji Takeda, Kazuhiko Nakagawa, Shinji Sasada and Shunishi Negoro. Journal of Clinical Trials6(6);279-81.2016
Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib. Takegawa N, Hayashi H, Iizuka N, Takahama T, Ueda H, Tanaka K, Takeda M, Nakagawa K. Ann Oncol. 27(5);953-5.2016
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer. Garon EB, Reck M, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Lee P, Dalal R, Liu J, He S, Treat J, Nakagawa K. Clin Lung Cancer.(16);30139-5 .2016
Two cases of EGFR mutation-positive lung adenocarcinoma that transformed into squamous cell carcinoma: successful treatment of one case with rociletinib. Haratani K, Hayashi H, Watanabe S, Kaneda H, Yoshida T, Takeda M, Shimizu T, Nakagawa K. Ann Oncol.27(1);200-2.2016
ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam KC, Muñoz-Antonia T, Qu X, Eschrich S, Uramoto H, Tanaka F, Nasarre P, Gemmill RM, Roche J, Drabkin HA, Haura EB. PLoS One. 2016 Jan 20;11(1):e0147344.

医局見学 随時受付中

オンコロジストを志す医師・学生の見学をいつでも受け入れています。